Gilead and Merus Announce Collaboration To Discover Novel Antibody-Based Trispecific T-Cell Engagers; Merus To Receive Upfront Cash Payment Of $56M For Initial Targets And Equity Investment By Gilead Of $25M in Merus Common Shares, Merus Is Also Eligible to Receive Up to $1.5B
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences, Inc. and Merus N.V. have entered into a collaboration to discover novel antibody-based trispecific T-cell engagers. Merus will receive an upfront cash payment of $56 million for initial targets and an equity investment by Gilead of $25 million in Merus common shares. Additionally, Merus is eligible to receive up to $1.5 billion.
March 06, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences invests $25M in Merus common shares and commits up to $1.5B for a collaboration on novel T-cell engagers.
Gilead's investment in Merus and the potential for up to $1.5 billion in payments indicate a significant commitment to this collaboration, likely to be viewed positively by investors as it expands Gilead's pipeline in innovative cancer therapies.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Merus receives $56M upfront and a $25M equity investment from Gilead, with eligibility for up to $1.5B, for a collaboration on novel T-cell engagers.
The upfront cash payment, equity investment, and potential for significant future payments from Gilead represent a major financial boost for Merus, likely to positively impact its stock price in the short term as it validates Merus's technology and pipeline.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90